Serological and experimental studies in different forms of myasthenia gravis. Issue 1 (29th January 2018)

• Record Type: Journal Article
• Authors: Vincent, Angela; Huda, Saif; Cao, Michelangelo; Cetin, Hakan; Koneczny, Inga; Rodriguez‐Cruz, Pedro; Jacobson, Leslie; Viegas, Stuart; Jacob, Saiju; Woodhall, Mark; Nagaishi, Akiko; Maniaol, Angelina; Damato, Valentina; Leite, M. Isabel; Cossins, Judith; Webster, Richard; Palace, Jacqueline; Beeson, David
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1413:Issue 1(2018)
• Page Start: 143
• Page End: 153
• Publication Date: 2018-01-29
• Subjects: myasthenia gravis -- muscle‐specific kinase -- clustered acetylcholine receptor -- low‐density lipoprotein receptor–related protein 4 -- active and passive immunization; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.13592
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract: Antibodies to the acetylcholine receptor (AChR) have been recognized for over 40 years and have been important in the diagnosis of myasthenia gravis (MG), and its recognition in patients of different ages and thymic pathologies. The 10–20% of patients who do not have AChR antibodies are now known to comprise different subgroups, the most commonly reported of which is patients with antibodies to muscle‐specific kinase (MuSK). The use of cell‐based assays has extended the repertoire of antibody tests to clustered AChRs, low‐density lipoprotein receptor–related protein 4, and agrin. Autoantibodies against intracellular targets, namely cortactin, titin, and ryanodine receptor (the latter two being associated with the presence of thymoma), may also be helpful as biomarkers in some patients. IgG4 MuSK antibodies are clearly pathogenic, but the coexisting IgG1, IgG2, and IgG3 antibodies, collectively, have effects that question the dominance of IgG4 as the sole pathologic factor in MuSK MG. After a brief historical review, we define the different subgroups and summarize the antibody characteristics. Experiments to demonstrate the in vitro and in vivo pathogenic roles of MuSK antibodies are discussed.